Baebies Announces CE Mark for FINDER, an Innovative Near-Patient Testing Platform for Glucose-6-Phosphate Dehydrogenase
DURHAM, NC / ACCESSWIRE / December 17, 2019 / Baebies is pleased to announce that FINDERTM, a near-patient testing platform, now has CE Mark as an In Vitro Diagnostic device (IVD) and is commercially available in Europe and other countries that recognize CE Mark. The CE-Marked platform includes an instrument and a cartridge, which tests for Glucose-6-Phosphate Dehydrogenase (G6PD) from low blood volume, a single drop of whole blood (50 μL), with a turn-around time of approximately 15 minutes after sample introduction.
G6PD deficiency is the most common enzyme deficiency worldwide, affecting approximately 400 million people. It can cause a spectrum of diseases including neonatal hyperbilirubinemia (HBR), commonly known as jaundice, acute hemolysis, and chronic hemolysis. “The ability to perform G6PD testing with a near-patient device would have a major impact on our ability to manage hyperbilirubinemia,” says Vinod Bhutani, MD, Professor of Pediatrics and Neonatology, Stanford University. “This would be especially valuable in areas of the world with high percentages of African, Asian, Mediterranean or Middle-Eastern descent, to provide a comprehensive profile of treatment and avoidance of stressors.”
To aid healthcare professionals in their clinical care for critically ill newborns and children undergoing intensive care, there is a significant need for tests requiring low blood volume. FINDER is specifically designed to address this growing need. FINDER can be used in various distributed settings including hospital nurseries, laboratories, neonatal intensive care units and birthing centers. The innovative, pioneering platform features:
- Digital microfluidic technology which minimizes sample and reagent volumes
- Small footprint at just 8 inches wide with a tablet for user interface
- Simple workflow with only one user step to load sample
- All necessary reagents onboard the cartridge, including for sample preparation
“As a company focused on newborn screening and pediatric testing, FINDER’s CE Mark allows Baebies to continue to work towards our mission, that everyone deserves a healthy start, by expanding access of testing to more babies around the world,” says Richard West, Co-Founder and Chief Executive Officer of Baebies.
FINDER is currently undergoing a clinical trial in the U.S. for Food and Drug Administration (FDA) clearance of the near-patient platform and the test panel that includes testing of G6PD enzyme activity. Baebies plans to complete the FINDER clinical trial in early 2020 for FDA 510(k) submission. Baebies has a robust development pipeline of test panels for various conditions requiring low blood volume to maximize diagnostic yield in neonatal and pediatric patients.
About Baebies
Baebies – guided by the vision that “everyone deserves a healthy start” – develops and commercializes products and services that enable early disease detection and comprehensive diagnosis for children. Baebies’ products include SEEKER®, an FDA-authorized and CE-marked high throughput newborn screening platform, and FINDERTM, a CE-marked low volume pediatric testing platform, currently not commercially available in the U.S. Our mission is to save lives and make lives better for all children by bringing new technologies, new tests and new hope to parents and healthcare professionals worldwide. To further our mission, Baebies also provides expanded newborn screening services from its CLIA-certified laboratory. Baebies is headquartered in Durham, North Carolina. For more information visit baebies.com and follow us on LinkedIn, Twitter and YouTube.
CONTACT:
Emily McLoughlin
emcloughlin @ baebies.com
(919) 328-8331
SOURCE: Baebies, Inc.
View source version on accesswire.com:
https://www.accesswire.com/570182/Baebies-Announces-CE-Mark-for-FINDER-an-Innovative-Near-Patient-Testing-Platform-for-Glucose-6-Phosphate-Dehydrogenase
